A Phase I, Multi-center, Open-label, Study of LXS196, an Oral Protein Kinase C Inhibitor, in Patients With Metastatic Uveal Melanoma

Trial Profile

A Phase I, Multi-center, Open-label, Study of LXS196, an Oral Protein Kinase C Inhibitor, in Patients With Metastatic Uveal Melanoma

Recruiting
Phase of Trial: Phase I

Latest Information Update: 06 Apr 2017

At a glance

  • Drugs LXS 196 (Primary)
  • Indications Uveal melanoma
  • Focus Adverse reactions
  • Sponsors Novartis Pharmaceuticals Corporation
  • Most Recent Events

    • 01 Mar 2017 Planned primary completion date changed from 24 Mar 2019 to 2 Oct 2017.
    • 08 Feb 2017 Planned number of patients changed from 53 to 100.
    • 08 Feb 2017 Planned End Date changed from 1 May 2018 to 24 Mar 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top